Publication | Closed Access

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept

InflammationCytokinePhase IiiImmunologyClinical TrialsPlacebo-controlled Clinical TrialsOutcomes ResearchTherapeutic EfficacyPharmacotherapyMedicine